Investigators reported high overall response rates and savings of roughly $1400 per patient across cohorts.
A study of British patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) who were treated with the rituximab biosimilar Truxima vs the originator (Rituxan) demonstrated comparable efficacy and tolerability between therapies, according to a recent study.
Investigators analyzed data from 201 patients treated by 46 UK-registered hematologists and oncologists in this retrospective survey. They evaluated charts for adult patients who received the biosimilar or originator as first-line immunotherapy between January 1, 2018, and June 30, 2019.
The use of biosimilar rituximab yielded not only comparable outcomes but also average cost savings of $1385 per patient. “These findings should inform decision makers on the potential for cost reductions where the biosimilar [Truxima] is available as a treatment alternative,” the investigators said.
They noted high overall response rates (ORRs) and 6-month progression-free survival (96%-98%) across cohorts, as well as 1-year survival of 98% to 100% across cohorts.
ORRs for patients with CLL who received Truxima vs Rituxan were 97.9% and 93.9%, respectively. For patients with NHL, the respective ORRs were 94.0% and 95.9%.
Complete response (CR) rates for patients receiving the biosimilar vs originator were 64.6% and 67.3% for CLL and 68.0% and 73.5% for NHL, respectively. Partial response rates were 33.3% and 26.5% for CLL and 26.0% and 22.4% for NHL.
Treatment discontinuations due to progression, death, or initiation of a subsequent line of therapy were 12.8% and 12.2 % for patients with CLL receiving Truxima vs Rituxan and 12.2% and 10.4% for patients in the NHL cohorts, respectively.
The investigators said 54% to 66% of patients across cohorts did not experience grade ≥ 3 adverse events (AEs); the most common grade ≥ 3 AEs were neutropenia, fatigue, anemia, and infusion reactions.
They did note high health care resource utilization, including drug costs, diagnostic testing, office visits with oncologists, and hospital admissions.
Reference
McBride A, Daniel S, Driessen MT, et al. Real-world overall response rate and other outcomes related to originator and biosimilar rituximab in patients with chronic lymphocytic leukemia or non-Hodgkin’s lymphoma in the United Kingdom. Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2021. Abstract e18696.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
January 16th 2025Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.